BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mayo SC, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind JF, Pawlik TM. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg 2013;216:123-34. [PMID: 23063263 DOI: 10.1016/j.jamcollsurg.2012.08.027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Spolverato G, Bagante F, Aldrighetti L, Poultsides G, Bauer TW, Field RC, Marques HP, Weiss M, Maithel SK, Pawlik TM. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. J Gastrointest Surg 2017;21:2039-47. [PMID: 28744737 DOI: 10.1007/s11605-017-3491-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chiruvella A, Kooby DA. Surgical Management of Pancreatic Neuroendocrine Tumors. Surgical Oncology Clinics of North America 2016;25:401-21. [DOI: 10.1016/j.soc.2015.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
3 Zhang XF, Beal EW, Weiss M, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis. J Surg Oncol. 2018;117:171-181. [PMID: 28940257 DOI: 10.1002/jso.24832] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fan KY, Wild AT, Halappa VG, Kumar R, Ellsworth S, Ziegler M, Garg T, Rosati LM, Su Z, Hacker-Prietz A, Pawlik TM, Cosgrove DP, Hong KK, Kamel IR, Geschwind JF, Herman JM. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemp Clin Trials 2016;50:143-9. [PMID: 27520932 DOI: 10.1016/j.cct.2016.08.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
5 Buicko JL, Finnerty BM, Zhang T, Kim BJ, Fahey TJ, Nancy Du YC. Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors. Ann Pancreat Cancer. 2019;2. [PMID: 31535089 DOI: 10.21037/apc.2019.06.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Zhang X, Beal EW, Chakedis J, Lv Y, Bagante F, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Weiss M, Pawlik TM. Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment. J Gastrointest Surg 2017;21:1821-30. [DOI: 10.1007/s11605-017-3490-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
7 Alagusundaramoorthy SS, Gedaly R. Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World J Gastroenterol 2014; 20(39): 14348-14358 [PMID: 25339822 DOI: 10.3748/wjg.v20.i39.14348] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
8 Desai GS, Pande P, Chhabra V, Shah RC, Jagannath P. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years. Indian J Gastroenterol 2019;38:399-410. [PMID: 31802438 DOI: 10.1007/s12664-019-00957-4] [Reference Citation Analysis]
9 Attarian S, Libutti SK, Chuy J. ACTH-Producing Pancreatic Neuroendocrine Tumor Presenting with Severe Hypokalemic Alkalosis: A Case Report. J Gastrointest Cancer 2016;47:217-20. [PMID: 26073616 DOI: 10.1007/s12029-015-9740-1] [Reference Citation Analysis]
10 Grąt M, Remiszewski P, Smoter P, Wronka K, Grąt K, Lewandowski Z, Koperski Ł, Górnicka B, Pacho R, Zborowska H, Patkowski W, Krawczyk M. Outcomes Following Liver Transplantation for Metastatic Neuroendocrine Tumors. Transplantation Proceedings 2014;46:2766-9. [DOI: 10.1016/j.transproceed.2014.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
11 Tan MC, Jarnagin WR. Surgical management of non-colorectal hepatic metastasis: Non-Colorectal Metastatectomy. J Surg Oncol 2014;109:8-13. [DOI: 10.1002/jso.23462] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
12 Spolverato G, Bagante F, Wagner D, Buettner S, Gupta R, Kim Y, Maqsood H, Pawlik TM. Quality of life after treatment of neuroendocrine liver metastasis. J Surg Res. 2015;198:155-164. [PMID: 26095419 DOI: 10.1016/j.jss.2015.05.048] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
13 Dong DH, Zhang XF, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Smith PM, Cho C, Beems M, Dillhoff M, Maithel SK, Pawlik TM. Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. HPB (Oxford) 2020;22:215-23. [PMID: 31235429 DOI: 10.1016/j.hpb.2019.05.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R. Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32-45. [PMID: 27236421 DOI: 10.1016/j.ctrv.2016.05.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
15 Zuckerman DA, Kennard RF, Roy A, Parikh PJ, Weiner AA. Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors-a single-institution experience. J Gastrointest Oncol 2019;10:118-27. [PMID: 30788167 DOI: 10.21037/jgo.2018.10.05] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
16 Graff-Baker AN, Sauer DA, Pommier SJ, Pommier RF. Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients. Surgery. 2014;156:1369-1376; discussion 1376-1377. [PMID: 25456912 DOI: 10.1016/j.surg.2014.08.009] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 7.5] [Reference Citation Analysis]
17 Pickens RC, Sulzer JK, Passeri MJ, Murphy K, Vrochides D, Martinie JB, Baker EH, Ocuin LM, McKillop IH, Iannitti DA. Operative Microwave Ablation for the Multimodal Treatment of Neuroendocrine Liver Metastases. J Laparoendosc Adv Surg Tech A 2021;31:917-25. [PMID: 33296283 DOI: 10.1089/lap.2020.0558] [Reference Citation Analysis]
18 Bhutiani N, Bruenderman EH, Jones JM, Wehry JH, Egger ME, Philips P, Scoggins CR, McMasters KM, Martin RCG. A literature-based treatment algorithm for low-grade neuroendocrine liver metastases. HPB (Oxford) 2021;23:63-70. [PMID: 32448647 DOI: 10.1016/j.hpb.2020.04.012] [Reference Citation Analysis]
19 Uri I, Grozinsky-Glasberg S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol. 2018;4:16. [PMID: 30009041 DOI: 10.1186/s40842-018-0066-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
20 Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: Recent advances and controversies. Curr Opin Gastroenterol. 2013;29:650-661. [PMID: 24100728 DOI: 10.1097/mog.0b013e328365efb1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
21 Bagante F, Spolverato G, Merath K, Postlewait LM, Poultsides GA, Mullen MG, Bauer TW, Fields RC, Lamelas J, Marques HP, Aldrighetti L, Tran T, Maithel SK, Pawlik TM. Neuroendocrine liver metastasis: The chance to be cured after liver surgery. J Surg Oncol 2017;115:687-95. [PMID: 28146608 DOI: 10.1002/jso.24563] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
22 Sahara K, Merath K, Tsilimigras DI, Hyer JM, Guglielmi A, Aldrighetti L, Weiss M, Fields RC, Poultsides GA, Maithel SK, Endo I, Pawlik TM, other members of the U.s. Neuroendo. Conditional disease‐free survival after curative‐intent liver resection for neuroendocrine liver metastasis. J Surg Oncol 2019;120:1087-95. [DOI: 10.1002/jso.25713] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Vilatobá M, Hurtado-Gómez S, García-Juárez I, Huitzil-Melendez D, Gamboa-Domínguez A. Liver transplantation in a patient with metastatic neuroendocrine tumor: A first report in Mexico. Rev Gastroenterol Mex (Engl Ed) 2019;84:414-6. [PMID: 31257111 DOI: 10.1016/j.rgmx.2018.09.002] [Reference Citation Analysis]
24 Barbier L, Neuzillet C, Dokmak S, Sauvanet A, Ruszniewski P, Belghiti J. Liver transplantation for metastatic neuroendocrine tumors. Hepat Oncol 2014;1:409-21. [PMID: 30190976 DOI: 10.2217/hep.14.21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Kim Y, Amini N, Wilson A, Margonis GA, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Weber SM, Salem A, Martin RC, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Cardona K, Maithel SK, Pawlik TM. Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Ann Surg Oncol. 2016;23:2998-3008. [PMID: 27169772 DOI: 10.1245/s10434-016-5262-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
26 Wiseman JT, Chakedis J, Beal EW, Paredes A, McElhany A, Fang A, Manilchuk A, Ellison C, Van Buren G, Pawlik TM, Schmidt CR, Fisher WE, Dillhoff M. Hemoglobin A1c Is a Predictor of New Insulin Dependence After Partial Pancreatectomy: A Multi-Institutional Analysis. J Gastrointest Surg 2021. [PMID: 33948858 DOI: 10.1007/s11605-021-05014-0] [Reference Citation Analysis]
27 Foss A, Lerut JP. Liver transplantation for metastatic liver malignancies. Curr Opin Organ Transplant 2014;19:235-44. [PMID: 24807212 DOI: 10.1097/MOT.0000000000000086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Armstrong EA, Beal EW, Shah M, Konda B, Abdel-Misih S, Ejaz A, Dillhoff ME, Pawlik TM, Cloyd JM. Radiographic characteristics of neuroendocrine liver metastases do not predict clinical outcomes following liver resection. Hepatobiliary Surg Nutr 2020;9:1-12. [PMID: 32140474 DOI: 10.21037/hbsn.2019.06.02] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
29 Uri I, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Update in the Therapy of Advanced Neuroendocrine Tumors. Curr Treat Options Oncol 2017;18:72. [PMID: 29143892 DOI: 10.1007/s11864-017-0514-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
30 Sharma N, Naraev BG, Engelman EG, Zimmerman MB, Bushnell DL Jr, OʼDorisio TM, OʼDorisio MS, Menda Y, Müller-Brand J, Howe JR, Halfdanarson TR. Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas 2017;46:151-6. [PMID: 27759712 DOI: 10.1097/MPA.0000000000000734] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
31 Spolverato G, Vitale A, Ejaz A, Kim Y, Cosgrove D, Schlacter T, Geschwind J, Pawlik TM. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. Surgery 2015;158:339-48. [DOI: 10.1016/j.surg.2015.03.033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
32 Chouliaras K, Newman NA, Shukla M, Swett KR, Levine EA, Sham J, Mann GN, Shen P. Analysis of recurrence after the resection of pancreatic neuroendocrine tumors. J Surg Oncol 2018;118:416-21. [PMID: 30259518 DOI: 10.1002/jso.25146] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
33 Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.Abdom Radiol (NY). 2020;. [PMID: 33095312 DOI: 10.1007/s00261-020-02833-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Spolverato G, Bagante F, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Weiss M, Pawlik TM. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis. J Surg Oncol 2017;116:298-306. [DOI: 10.1002/jso.24670] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
35 Xiang J, Zhang X, Weiss M, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis. Ann Surg Oncol 2020;27:3717-26. [DOI: 10.1245/s10434-020-08620-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Devcic Z, Rosenberg J, Braat AJ, Techasith T, Banerjee A, Sze DY, Lam MG. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med 2014;55:1404-10. [PMID: 25012459 DOI: 10.2967/jnumed.113.135855] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
37 Michalski CW, Billingsley KG. Modern technical approaches in resectional hepatic surgery. Surg Oncol Clin N Am 2015;24:57-72. [PMID: 25444469 DOI: 10.1016/j.soc.2014.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
38 Onesti JK, Shirley LA, Saunders ND, Davidson GW, Dillhoff ME, Khabiri H, Guy GE, Dowell JD, Schmidt CR, Shah MH, Bloomston M. Elevated Alkaline Phosphatase Prior to Transarterial Chemoembolization for Neuroendocrine Tumors Predicts Worse Outcomes. J Gastrointest Surg 2016;20:580-6. [PMID: 26489743 DOI: 10.1007/s11605-015-2998-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
39 Xiang JX, Zhang XF, Weiss M, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome. J Surg Oncol 2018;118:1096-104. [PMID: 30261105 DOI: 10.1002/jso.25246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
40 Pacella CM, Nasoni S, Grimaldi F, Di Stasio E, Misischi I, Bianchetti S, Papini E. Laser ablation with or without chemoembolization for unresectable neuroendocrine liver metastases: a pilot study. International Journal of Endocrine Oncology 2016;3:97-107. [DOI: 10.2217/ije.15.34] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
41 Feuerecker B, Scheidhauer K, Schwaiger M, Mustafa M. Intra-arterial radiopeptide therapy of hepatic metastases of neuroendocrine tumors: a systematic review. Clin Transl Imaging 2017;5:89-99. [DOI: 10.1007/s40336-016-0220-9] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
42 Chakedis J, Beal EW, Lopez-aguiar AG, Poultsides G, Makris E, Rocha FG, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Marincola-smith P, Cho C, Beems M, Pawlik TM, Maithel SK, Schmidt CR, Dillhoff M. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. J Gastrointest Surg 2019;23:122-34. [DOI: 10.1007/s11605-018-3986-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]